![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/a/a5/Futibatinib.svg/640px-Futibatinib.svg.png&w=640&q=50)
Futibatinib
Chemical compound / From Wikipedia, the free encyclopedia
Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of cholangiocarcinoma (bile duct cancer).[1][3] It is a kinase inhibitor.[1][6] It is taken by mouth.[1]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Lytgobi |
Other names | TAS-120 |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data |
|
Routes of administration | By mouth |
Drug class | Antineoplastic |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C22H22N6O3 |
Molar mass | 418.457 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
Futibatinib was approved for medical use in the United States in September 2022,[1][3][7][2] in Japan in June 2023[8][9] and in the European Union in July 2023.[4][10]